Merus
Utrecht, NL · 1 known investors
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
BiotechMedical Devices
Investors · 1
In the news
- Genmab’s Merus Deal Forced Analysts To Rethink Earnings - Finimizefinimize.com · 2026
- Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares | Nasdaqnasdaq.com · 2025
- Merus - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Merus capital raises $85 mln for venture firm's third fund | Reutersreuters.com · 2017
- Dutch Biotech Merus Raises €21.7 Million | Fierce Biotechfiercebiotech.com · 2010
- Buy Merus Stock – MRUS Stock Quote Today & Investment Insights - Public.compublic.com